Anaplastic lymphoma kinase inhibitor-associated myositis
Open Access
- 6 May 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Anaplastic lymphoma kinase (ALK) inhibitors have been used in patients with non-small cell lung cancer (NSCLC) harboringEML4-ALKfusion gene.(1)Severe skeletal muscle adverse events of ALK inhibitors, such as muscle weakness, have seldom been reported.(2,3)Herein, we describe a patient who showed a severe skeletal muscle deficit after the administration of the ALK inhibitor, alectinib, and was successfully treated by corticosteroids without withdrawal from the cancer therapy.Keywords
This publication has 5 references indexed in Scilit:
- The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysisCancer Management and Research, 2019
- Inflammatory myopathy associated with PD-1 inhibitorsJournal of Autoimmunity, 2019
- Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancerNeurology, 2018
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- Sequential Therapy with Crizotinib and Alectinib in ALK -Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective StudyJournal of Thoracic Oncology, 2016